A detailed history of Lion Point Capital, LP transactions in Lumos Pharma, Inc. stock. As of the latest transaction made, Lion Point Capital, LP holds 39,589 shares of LUMO stock, worth $171,816. This represents 0.41% of its overall portfolio holdings.

Number of Shares
39,589
Previous 90,794 56.4%
Holding current value
$171,816
Previous $210,000 27.14%
% of portfolio
0.41%
Previous 0.45%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.45 - $4.05 $74,247 - $207,380
-51,205 Reduced 56.4%
39,589 $153,000
Q3 2023

Nov 14, 2023

BUY
$2.63 - $3.49 $32,725 - $43,426
12,443 Added 15.88%
90,794 $299,000
Q2 2023

Aug 14, 2023

BUY
$3.01 - $4.38 $81,709 - $118,899
27,146 Added 53.01%
78,351 $258,000
Q4 2021

Feb 14, 2022

SELL
$6.84 - $10.04 $2.43 Million - $3.57 Million
-355,987 Reduced 87.42%
51,205 $354,000
Q1 2020

May 15, 2020

BUY
$0.89 - $8.85 $362,400 - $3.6 Million
407,192 New
407,192 $3.46 Million

Others Institutions Holding LUMO

About LUMOS PHARMA, INC.


  • Ticker LUMO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 8,396,070
  • Market Cap $36.4M
  • Description
  • Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare en...
More about LUMO
Track This Portfolio

Track Lion Point Capital, LP Portfolio

Follow Lion Point Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lion Point Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Lion Point Capital, LP with notifications on news.